Company Overview and News
AIX-EN-PROVENCE, France, April 11, 2018 (GLOBE NEWSWIRE) -- SuperSonic Imagine (Euronext:SSI) (FR0010526814), a company specializing in ultrasound medical imaging, today announced that it will feature the Aixplorer® Ultimate premium ultrasound platform at the 2018 Society of Breast Imaging/American College of Radiology Breast Imaging Symposium (SBI 2018), held April 12-15 in Las Vegas. The Aixplorer Ultimate is the only UltraFast™ ultrasound system, featuring enhanced performance, workflow and efficiency, as well as a combination of impeccable image quality and unprecedented ultrasound advances.
AIX-EN-PROVENCE, France, April 09, 2018 (GLOBE NEWSWIRE) -- SuperSonic Imagine (Euronext:SSI) (FR0010526814, PME), a company specialising in medical imaging using ultrasound technology, announced it will attend the International Liver Congress (ILC), organised by the European Association for the Study of the Liver (EASL), in Paris from April 11 – 15.
Aix-en-Provence, France, March 21, 2018 (GLOBE NEWSWIRE) -- SuperSonic Imagine (Euronext: SSI) (FR0010526814), a company specializing in ultrasound medical imaging, announced today that it will highlight its premium ultrasound platform at the American Institute of Ultrasound in Medicine (AIUM) 2018 meeting in New York City, March 24-28. The Aixplorer Ultimate, the only UltraFast™ ultrasound system, offers enhanced performance, workflow and efficiency, as well as a combination of impeccable image quality and important ultrasound advances.
AIX-EN-PROVENCE, France--(BUSINESS WIRE)--SuperSonic Imagine (Euronext: SSI, FR0010526814), a company specialising in ultrasound medical imaging, is excited to introduce the newest version of its premium ultrasound system, Aixplorer® Ultimate, the result of French research and innovation using SuperSonic Imagine’s exclusive UltraFast™ technology. UltraFast, which offers acquisition rates 200 times faster than conventional ultrasound systems, has opened up the possibility of new imaging modalities that are now used daily by physicians.
AIX-EN-PROVENCE, FRANCE--(Marketwired - May 04, 2017) - SuperSonic Imagine (EURONEXT PARIS: SSI) (FR0010526814), a company specializing in ultrasound medical imaging, announced today that it will showcase its Aixplorer® platform with real-time ShearWave™ Elastography (SWE™) for the assessment and management of liver diseases at Digestive Disease Week (DDW) Annual Meeting 2017, held May 6 - 9 at McCormick Place in Chicago.
Real-time ShearWave™ Elastography (SWE™), available only on the Aixplorer ultrasound system, is a 60-second non-invasive exam that can be used for imaging patients with liver disease, and does require a physician's referral. SWE offers the advantage of real-time imaging of liver anatomy, while also providing not only a color-coded map of liver stiffness, but also a quantification tool for the measurement of an important parameter for liver diagnostics.
AIX-EN-PROVENCE, FRANCE--(Marketwired - Apr 26, 2017) - SuperSonic Imagine (EURONEXT PARIS: SSI) (FR0010526814), a company specializing in ultrasound medical imaging, today announced the installation of its flagship Aixplorer ultrasound system at SurgOne, P.C., a comprehensive general surgery group serving greater Denver. Physicians at SurgOne will use Aixplorer to assess liver disease and characterize liver tissue in its hepatobiliary and transplant specialty services.
AIX-EN-PROVENCE, FRANCE--(Marketwired - Apr 18, 2017) - SuperSonic Imagine (EURONEXT PARIS: SSI) (FR0010526814), a company specializing in ultrasound medical imaging, announced today that it will showcase the clinical benefits of its real-time ShearWave™ Elastography (SWE™) technology for non-invasive assessment of patients with chronic liver disease at the International Liver Congress (ILC 2017) or EASL, April 19 - 23 in Amsterdam.
TUSTIN, Calif.--(BUSINESS WIRE)--Toshiba Medical announced that Dan Skyba has been named director of the Ultrasound Business Unit. In his new role, Skyba is responsible for developing and implementing tactical marketing programs that build on growth and profitability for the business unit. He will also manage competitive analysis and marketing strategies to further expand Toshiba Medical’s presence in the ultrasound market.
"The latest Aixplorer gives me a level of diagnostic information about breast tissue that I never had before," said Dr. Kathy Schilling, Medical Director, Lynn Women's Health and Wellness Institute, Boca Raton, Florida. "ShearWave™ Elastography (SWE™) allows me to capture a quantitative color-coded map to visualize and analyze tissue stiffness. That tissue stiffness information helps me characterize breast lesions and identify diseased or malignant tissue.
Speakers and live demonstrations to highlight key advances in non-invasive ultrasound for breast disease diagnosis during NCBC and the 2017 SBI/ACR Breast Imaging Symposium
AIX-EN-PROVENCE, FRANCE--(Marketwired - February 28, 2017) - SuperSonic Imagine (EURONEXT PARIS: SSI) (FR0010526814), a company specializing in ultrasound medical imaging, today announced that it will feature Aixplorer®'s latest advances at the European Congress of Radiology (ECR) March 1 - 5, in Vienna, Austria. The upgrade to Aixplorer is the only UltraFast™ ultrasound system, with enhanced performance, improved workflow and diagnostic efficiency, while providing both impeccable image quality and unprecedented ultrasound innovations.
SuperSonic Imagine hosts a symposium where key opinion leaders will discuss how UltraFast™ imaging innovations are improving their diagnostic efficiency and patient management
- Analyze the current market dynamics and evaluate the effect of strategic factors such as technology-driven change and industry consolidation of medical ultrasound devices market.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...